Information about Lipaspan
Composition:
LIPASPAN ER Tablets for oral administration contain: 500 or 1000 mg of Niacin.

Indications and usage:

Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate, as follows:

1. To patients with primary hyperlipidemia and mixed dyslipidemia.

2. In combination with lipid lowering products as statins derivatives , for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with Niacin or statins monotherapy is considered inadequate.

3. To patients with a history of myocardial infarction and hyperlipidemia. it is indicated to reduce the risk of recurrent nonfatal myocardial infarction.

4. To patients with a history of coronary artery disease (CAD) and hyperlipidemia, it is indicated in combination with a bile acid binding resin, to slow progression or regression of atherosclerotic disease.

5. In combination with a bile acid binding resin, it is indicated to reduce elevated TC and lDl-C levels in adult patients with primary hyperlipidemia (Type IIa).

6. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.

Dosage and administration:

Lipaspan extended-Release should be taken at bedtime, after a low-fat snack, and individualized according to patient response.

Therapy with Lipaspan extended-Release must be initiated at 500 mg at bedtime.

Initiation of therapy:

1 to 4 weeks 500 mg daily at bedtime

5 to 8 weeks 1000 mg daily at bedtime, Thereafter "According to response" 1500 to 2000mg daily at bedtime.

The daily dosage of Lipaspan extended-Release should not be increased by more than 500 mg in any 4-week period and doses above 2000 mg daily are not recommended.

Package:

Pack of 28 F.C Tablets for each strength.